Breaking News

Center for Breakthrough Medicines and jCyte Ink Manufacturing Deal

Multi-year deal to focus on phase 3 clinical trial supplies and commercial manufacturing.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

The Center for Breakthrough Medicines (CBM), a contract development and manufacturing organization (CDMO) dedicated to addressing the requirements associated with commercializing cell and gene therapies, and jCyte, a clinical-stage biotech focused on preserving and restoring vision in patients with retinitis pigmentosa (RP) and other retinal degenerative diseases, entered a multi-year manufacturing agreement wherein CBM will be the primary manufacturer of jCyte’s U.S. FDA’s Regenerative Me...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters